Swedbank AB Cuts Stake in Amgen Inc. $AMGN

Key Points

• Swedbank AB trimmed its stake in Amgen by 16.4%, selling 79,844 shares to hold 405,559 shares worth about $132.7 million per its latest SEC filing.
• Amgen beat Q1 expectations with EPS $5.15 vs. $4.77 and revenue of $8.62 billion, set FY2026 guidance of 21.700–23.100 EPS, and declared a quarterly dividend of $2.52 (~3.0% yield; ex‑dividend May 15).
• Analyst sentiment is mixed — the consensus rating is Hold with an average target of $357.12, although some firms (RBC, Piper Sandler) raised targets while Guggenheim trimmed its target to $340.

Swedbank AB cut its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 16.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 405,559 shares of the medical research company's stock after selling 79,844 shares during the quarter. Swedbank AB owned about 0.08% of Amgen worth $132,744,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. West Family Investments Inc. raised its holdings in Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company's stock worth $779,000 after acquiring an additional 30 shares during the last quarter. Viawealth LLC boosted its stake in Amgen by 0.4% during the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company's stock valued at $2,023,000 after purchasing an additional 30 shares during the last quarter. LOM Asset Management Ltd boosted its stake in Amgen by 1.2% during the 3rd quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company's stock valued at $721,000 after purchasing an additional 30 shares during the last quarter. Sittner & Nelson LLC increased its holdings in shares of Amgen by 0.4% in the 3rd quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company's stock worth $2,053,000 after purchasing an additional 30 shares in the last quarter. Finally, Smith Salley Wealth Management increased its holdings in shares of Amgen by 0.3% in the 4th quarter. Smith Salley Wealth Management now owns 10,786 shares of the medical research company's stock worth $3,530,000 after purchasing an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company's stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company's stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company's stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a $300 million expansion of its U.S. biologics manufacturing footprint (including a major Puerto Rico investment) to boost capacity and supply-chain resilience — a move investors view as supportive of long‑term revenue stability for its biologics portfolio. Amgen’s US$300m Biologics Push And What It Means For AMGN Stock
• Positive Sentiment: BMO Capital initiated (or reiterated) a Buy on AMGN, providing buy-side support that can help lift sentiment and buying interest. Amgen (AMGN) Gets a Buy from BMO Capital
• Positive Sentiment: Amgen confirmed a quarterly dividend ($2.52 / share; ~3.1% yield) and an upcoming ex-dividend date, which supports income-oriented investor demand. MarketBeat Dividend Coverage
• Neutral Sentiment: Analysts’ views are mixed across the healthcare/biotech group and on AMGN specifically — some firms maintain hold/market‑perform stances while others remain constructive. That produces uneven broker flow rather than a clear directional push. Analysts’ Opinions Are Mixed on These Healthcare Stocks
• Neutral Sentiment: Comparative valuation pieces (e.g., RPRX vs AMGN) are circulating — useful for positioning but unlikely to drive immediate share moves absent fresh data or analyst target changes. RPRX vs. AMGN: Which Stock Is the Better Value Option?
• Neutral Sentiment: Insider activity: an Amgen SVP sold ~1,237 shares (~$400k) in early May — a disclosed sale that can draw attention but is modest relative to institutional ownership and not necessarily indicative of company fundamentals. SEC Filing - Form 4
• Negative Sentiment: Competitive risk: Viridian Therapeutics reported encouraging data for a thyroid eye disease candidate that could challenge Amgen’s Tepezza franchise if development/regulatory paths stay positive — increased competition can pressure future sales and margin assumptions. Viridian data lift prospects for thyroid eye disease drug
• Negative Sentiment: Guggenheim trimmed its price target on AMGN (to $340) while keeping a neutral/hold stance — a modest analyst-downward revision that can cap upside from analyst-driven buying. Guggenheim Trims Amgen Price Target

Analysts Set New Price Targets

Several research firms recently commented on AMGN. Royal Bank Of Canada increased their price objective on Amgen from $360.00 to $370.00 and gave the company an "outperform" rating in a research report on Tuesday, April 7th. Wall Street Zen cut shares of Amgen from a "buy" rating to a "hold" rating in a research note on Saturday, April 25th. TD Cowen reaffirmed a "buy" rating on shares of Amgen in a report on Wednesday, February 4th. Piper Sandler lifted their price target on shares of Amgen from $381.00 to $432.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 18th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Amgen from $285.00 to $295.00 and gave the company a "hold" rating in a report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $357.12.

Amgen Stock Up 0.5%

AMGN stock opened at $331.11 on Thursday. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The business's 50-day moving average is $356.20 and its two-hundred day moving average is $341.60. The company has a debt-to-equity ratio of 5.65, a quick ratio of 0.90 and a current ratio of 1.26. The company has a market cap of $178.69 billion, a price-to-earnings ratio of 23.04, a P/E/G ratio of 3.32 and a beta of 0.44.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the previous year, the company posted $4.90 EPS. The business's quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts forecast that Amgen Inc. will post 22.36 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen's payout ratio is 70.15%.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.